Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nyxoah SA - Ordinary Shares (NQ:NYXH)

7.000 -0.020 (-0.28%)
Streaming Delayed Price Updated: 11:43 AM EDT, Aug 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nyxoah SA - Ordinary Shares

< Previous 1 2 3 4 5 Next >
Nyxoah Announces Preliminary Results for the Second Quarter of 2025
From Nyxoah
Via GlobeNewswire
Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea
From Nyxoah
Via GlobeNewswire
Information on the total number of voting rights and shares
From Nyxoah
Via GlobeNewswire
Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025
From Nyxoah
Via GlobeNewswire
Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine
From Nyxoah
Via GlobeNewswire
Information on the total number of voting rights and shares
From Nyxoah
Via GlobeNewswire
Invitation to attend the extraordinary shareholders’ meeting of the Company to be held on July 2, 2025
From Nyxoah
Via GlobeNewswire
Publication relating to transparency notifications
From Nyxoah
Via GlobeNewswire
Nyxoah to Present at the Jefferies Global Healthcare Conference
From Nyxoah
Via GlobeNewswire
Information on the total number of voting rights and shares
From Nyxoah
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
From Pomerantz LLP
Via GlobeNewswire
Nyxoah Reports First Quarter Financial and Operating Results
From Nyxoah
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Nyxoah S.A. – NYXH
From Pomerantz LLP
Via GlobeNewswire
Publication relating to transparency notifications
From Nyxoah
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
From Pomerantz LLP
Via GlobeNewswire
Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 11, 2025
From Nyxoah
Via GlobeNewswire
Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025
From Nyxoah
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Nyxoah S.A. - NYXH
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
From Pomerantz LLP
Via GlobeNewswire
Conditional Issuance of Shares
From Nyxoah
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
From Pomerantz LLP
Via GlobeNewswire
Nyxoah Provides Update on FDA Approvable Letter for Genio System
From Nyxoah
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
From Pomerantz LLP
Via GlobeNewswire
NYXH Investors Have Opportunity to Join Nyxoah S.A. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
From Pomerantz LLP
Via GlobeNewswire
FDA Issues Nyxoah an Approvable Letter for its Genio® System
From Nyxoah
Via GlobeNewswire
Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results
From Nyxoah
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.